Lyme Disease Patient Trajectories Learned from Electronic Medical Data for Stratification of Disease Risk and Therapeutic Response

Osamu Ichikawa1,2, Benjamin S. Glicksberg1,3, Nicholas Genes4, Brian A. Kidd1, Li Li1,5 & Joel T. Dudley1

Lyme disease (LD) is the most common tick-borne illness in the United States. Although appropriate antibiotic treatment is effective for most cases, up to 20% of patients develop post-treatment Lyme disease syndrome (PTLDS). There is an urgent need to improve clinical management of LD using precise understanding of disease and patient stratification. We applied machine-learning to electronic medical records to better characterize the heterogeneity of LD and developed predictive models for identifying medications that are associated with risks of subsequent comorbidities. For broad disease categories, we identified 3, 16, and 17 comorbidities within 2, 5, and 10 years of diagnosis, respectively. At a higher resolution of ICD-9 codes, we identified known associations with LD including chronic pain and cognitive disorders, as well as particular comorbidities on a timescale that matched PTLDS symptomology. We identified 7, 30, and 35 medications associated with risks of these comorbidities within 2, 5, and 10 years, respectively. For instance, the first-line antibiotic doxycycline exhibited a consistently protective association for typical symptoms of LD, including backache. Our approach and findings may suggest new hypotheses for more personalized treatments regimens for LD patients.

Lyme disease (LD) is a vector-borne, infectious disease caused by the bacterium Borrelia burgdorferi that is transmitted to humans through tick bites. According to the US Centers for Disease Control and Prevention (CDC), around 329,000 LD cases occur annually1 and it becomes a major US public health problem that causes substantial use of health care resources. LD is most prevalent in the Northeast and upper Midwest, and 95% of all confirmed cases in 2015 were reported in 14 states2. The symptomology of LD is heterogeneous, although some general patterns have emerged. The first manifestation of LD is often an expanding annular lesion, called erythema migrans, near the bite location, but this sign is present in only 70–80% of patients3. The length of time for the rash to occur, along with the characteristics of the rash (e.g., composition and size) can also vary4. Other clinical features that often arise, singly or in combination, include fever, pain, arthritis, neurological symptoms (e.g., facial nerve palsy), and satellite rashes. One explanation for the variability in Lyme Disease (LD) symptoms is that the genotype of the Borrelia burgdorferi itself might affect aspects of pathogenesis, such as the probability of hematogenous dissemination5,6. The neurological manifestations in LD, reported in 3–12% of patients, are of great concern7. These phenomena, collectively called neuroborreliosis, are often associated with intense pain that can manifest either soon after infection or much later, from months to years afterward.

Accurate and precise diagnoses of LD present several challenges. Typically, laboratory testing of LD follows identification of cutaneous manifestations from visual inspection but these manifestations are not always present (see Supplementary Background for further exploration of issues regarding laboratory testing for LD). Many
studies have attempted to develop methods for differentiating LD from other similar syndromes, e.g., septic arthritis vs. LD of the knee in children.\(^4\)

Following successful diagnosis, LD is most commonly treated with antibiotics such as doxycycline, amoxicillin, cefuroxime axetil, and ceftriaxone. Although these medications have high cure rates (\(\sim 90\%\))\(^9\), they are associated with serious complications and adverse events, especially under prolonged use\(^4,10-14\). One study even showed that certain first-line treatments, specifically intravenous ceftriaxone followed by doxycycline for chronic symptoms in LD, were not effective compared to placebo forcing discontinuation of the trial\(^1\). Another study reported that repeated IV ceftriaxone treatment for Lyme encephalopathy resulted in only minor cognitive improvements, with high rates of relapse of cognitive symptoms\(^1\). These findings suggest that unknown factors are responsible for the high variability of treatment outcomes for patients with disseminated LD. Additionally, up to 20% of treated patients develop post-treatment Lyme disease syndrome (PTLDS), in which lingering symptoms such as fatigue, pain, or joint and muscle aches last for months or even years. The causes and frequencies of these symptoms remain unclear, and the issue is further confounded by the presence of concurrent diseases.

It is difficult to disentangle to what extent given treatment responses and disease sequelae are due to differences in individual immune responses, patient characteristics, disease burden, and treatment timing, or to the medications themselves. Indeed, it is very likely that response and outcome depend on a complex interplay between these factors, making clinicians’ jobs extremely difficult\(^5,6\). To address the diverse symptomology, imperfect diagnostic strategies (see Supplementary Background), and variable treatment outcomes of LD, comprehensive study designs are required.

Although the aforementioned studies have provided a great deal of useful information, the variability in global risk profiles for LD pathogenesis remains incompletely understood, and there is an unmet need for personalized treatment recommendations that take into account individual characteristics and disease burden. Electronic Medical Records (EMRs) from hospitals contain a wealth of longitudinal, patient-level data encompassing prior history of prescriptions and disease diagnoses, along with clinical outcomes, that can be exploited to investigate these issues in a data-driven fashion PMID: 29659828. To date there has been no systematic analysis of LD using EMR data, particularly from a hospital within a high-risk state (see Supplementary Background).

We hypothesized that EMR data from Mount Sinai Hospital in New York City could provide a rich framework for studying the heterogeneity of Lyme manifestation, as well as the quality and efficacy of treatment. Using various state-of-the-art statistical and machine learning methods, our study is the first data-driven effort to prioritize medications for LD based on an individual’s phenotype profile. We identified Lyme-associated comorbidities at the level of broad disease categories, pinpointed specific co-morbid diseases associated with LD over time, including the diseases known to follow LD, and we predicted medications that associate with risk of developing these comorbidities (Fig. 1). We expect that the novel framework and findings from this study can be used to support future efforts to develop personalized treatment strategies for patients with LD, including providing physicians with a broader evidentiary foundation on which to base their treatment recommendations (e.g., selection of antibiotics) based on individual patients’ disease background.

Results

Identified comorbidities associated with Lyme disease, grouped as broader disease categories.

We assessed the temporal ordering of the associations between Lyme disease (LD) and other diseases (grouped by CCS category) to determine whether a given comorbidity tended to occur before or after diagnosis of LD. We categorized diseases using the Clinical Classifications Software (CCS) for ICD-9 diagnosis codes, developed by AHRQ 14, which aggregates and characterizes more than 14,000 ICD-9 codes into broader coherent 283 disease categories (Supplemental Methods). This strategy helps to avoid sample size limitation as a result of using ICD-9 codes alone. We restricted our analysis to diseases with reported dates and only included the first reported encounter of a diagnosis and analyzed their temporal ordering at the patient level. For each comorbid disease pair (i.e., LD and another disease category), we tabulated the number of patients with both diseases and assessed which disease in the pair occurred first, or if they occurred at the same time, based on the visit dates. Out of the 275 Lyme-comorbidity combinations (restricting to those with at least 20 affected patients of both conditions) for all time windows, 21 were nominally significant, with 5 diseases occurring prior to LD and 16 occurring after \((p < 0.1\) due to the relatively small sample size; Table 1). For the 2-year window, we identified three disease categories significantly associated with LD, with two prior and one after; for the 5-year window, 16 categories, with four prior and 12 after; and for the 10-year window, 17 categories with five prior and 12 after (Table 1). We confirmed some reported Lyme comorbidities, including ‘nutritional deficiencies’\(^17,18\), ‘vision defect’\(^19,20\), and ‘disorder of lipid metabolism’\(^21\). Additionally, we identified several disease comorbidities not previously reported, including ‘cataract’, ‘acute bronchitis’ and ‘nonmalignant breast conditions’. A complete list of disease categories is shown in Table 1.

Highlighted specific known or novel diseases associated with LD, analyzed at higher resolution.

Although the CCS broad categories were helpful in identifying disease groups of relevance from a broader perspective, we also performed the same analysis at a higher granularity (Table 2 and Supplementary Table 1). To this end, using the ICD-9 codes, we sought to determine which specific diseases drove the signal and whether the signal still persisted. A total of 3,639 Lyme–comorbidity combinations were analyzed using the ICD-9 codes. We identified known associations that occur within a 10-year window after LD \((p < 0.1\) due to the relatively small sample size). We found associations relating to pain, including ‘chronic pain Not Elsewhere Classifiable (NEC)’ \((p = 0.015)\), ‘joint pain-shoulder (shoulder)’ \((p = 0.047)\), ‘pain in limb’ \((p = 0.074)\), ‘throat pain’ \((p = 0.001)\), and ‘tension headache Not Otherwise Specified (NOS)’ \((p = 0.063)\) (Supplementary Table 1). We also identified
associations related to cognitive issues, specifically 'dementia NOS w behavioral (behav) disturbance (distrb)' (p = 0.016), 'dementia NOS w/o behavioral (behv) disturbance (dstrb)' (p = 0.006), and 'Alzheimer’s disease' (p = 0.073).

At the 2-year window, five pairs were nominally significant, with four prior to LD and one after (Supplementary Table 1). For the 5-year window, we found 53 significant associations, with 49 prior to LD and four afterwards. For the 10-year window, we found 75 significant associations, with 67 prior to LD diagnosis and eight after. The significance of all disease categories significantly associated with LD that we identified in the previous ICD-level analysis persisted, including the four diseases that significantly occurred prior to LD: ‘pure hypercholesterolemia’ (p = 0.080 at 10 years), ‘hyperlipidemia NEC/NOS’ (p = 0.090 at 10 years), ‘hypertension NOS’ (p = 0.082 at 10 years), and ‘coronary atherosclerosis (athero) NOS’ (p = 0.022 at 5 years; p = 0.075 at 10 years). Nine sequelae diseases of are particular interest, specifically: ‘vitamin D deficiency NOS’ (p = 0.014 at 5 years; p = 0.0047 at 10 years), ‘cataract NOS’ (p = 0.041 at 5 years; p = 0.030, prob = 0.62 at 10 years), ‘senile nuclear cataract’ (p = 0.0013 at 10 years), ‘tear film insufficiency (insuffic) NOS’ (p = 0.033 at 10 years), ‘acute bronchitis’ (p = 0.015 at 5 years; p = 0.017 at 10 years) and ‘HIV positive NOS’ (p = 0.012 at 5 years; p = 0.0035 at 10 years) drove the signal from the broad disease categories (Table 2).

We confirmed the large majority of the comorbidity pairs were significantly associated with LD with concordant directionality by adjusting age, gender, and race by logistic regression (p < 0.1). Many of these include known associations mentioned above. We provide a complete list of ICD-9 level disease associations that passed our significance threshold in both analyses (Supplementary Table 1).

**Medications predicted to modulate risk of subsequent comorbidities in LD patients, analyzed as broader disease categories.** To investigate associations between prescribed medications and development of subsequent disease pathogenesis, we focused on comorbidities with onset after the first diagnosis of LD. Using the adaptive LASSO methodology and a logistic regression model, we investigated all medications prescribed to LD patients prior to the comorbidities. We found 3, 12, and 18 medications associated with disease comorbidities, classified by CCS-single-level categories, within 2, 5, and 10 years after Lyme diagnosis, respectively (Supplementary Table 2, Fig. 2A,B). Four medication–LD comorbidity associations were supported by...
https://doi.org/10.1038/s41598-019-41128-x

In regard to ‘nutritional deficiencies’, 11 medications were predicted to be risk factors and three to be protective. Five antibiotics, doxycycline, azithromycin, levofloxacin, clavulanate, and mupirocin, and one antiviral drug, valacyclovir, were predicted to modulate the risk of subsequent comorbidities. Doxycycline, a first-line antibiotic that was the most prescribed antibiotic in our EMR for patients with LD (39%, N = 553), was associated with an elevated risk of eye disorders, including ‘cataract’ (adjusted OR = 2.58, p = 0.033 at 10 years), ‘blindness and vision defects’ (adjusted OR = 2.23, p = 0.031 at 5 years; adjusted OR = 2.48, p = 0.0092 at 10 years), metformin–‘nutritional deficiencies’ (adjusted OR = 2.63, p = 0.097 at 10 years), and esomeprazole–‘nutritional deficiencies’ (adjusted OR = 1.75, p = 0.093 at 10 years).

Table 1. Diseases associated with Lyme, analyzed as CCS-single-level categories (p value < 0.1). A total of 275 diseases were tested.

| Time (year) | Direction | Disease (CCS) | Lyme First | Disease First | Same Time | P value | Prob. | Time | Direction | Disease (CCS) | Lyme First | Disease First | Same Time | P value | Prob. |
|------------|-----------|---------------|------------|---------------|-----------|---------|-------|------|-----------|---------------|------------|---------------|-----------|---------|-------|
| 2          | —         | Coronary atherosclerosis and other heart disease | 18         | 58            | 17        | 1.10E-02 | 0.62  |
| 2          | —         | Administrative/social admission | 41         | 66            | 9         | 8.17E-02 | 0.57  |
| 2          | +         | Acute bronchitis | 23         | 11            | 3         | 9.39E-02 | 0.62  |
| 5          | —         | HIV infection | 2          | 21            | 9         | 5.51E-02 | 0.66  |
| 5          | —         | Coronary atherosclerosis and other heart disease | 38         | 80            | 17        | 1.92E-02 | 0.59  |
| 5          | —         | Administrative/social admission | 55         | 88            | 9         | 3.09E-02 | 0.58  |
| 5          | —         | Disorders of lipid metabolism | 117        | 269           | 111       | 3.63E-02 | 0.54  |
| 5          | +         | Open wounds of extremities | 24         | 6             | 0         | 7.15E-04 | 0.8   |
| 5          | +         | Open wounds of head; neck; and trunk | 19         | 9             | 0         | 4.36E-02 | 0.68  |
| 5          | +         | Fracture of lower limb | 16         | 8             | 0         | 7.58E-02 | 0.67  |
| 5          | +         | Cataract | 57         | 21            | 10        | 3.67E-03 | 0.65  |
| 5          | +         | Fracture of upper limb | 18         | 9             | 1         | 9.25E-02 | 0.64  |
| 5          | +         | Acute bronchitis | 36         | 17            | 3         | 2.20E-02 | 0.64  |
| 5          | +         | Anal and rectal conditions | 26         | 11            | 5         | 8.31E-02 | 0.62  |
| 5          | +         | Nonmalignant breast conditions | 60         | 36            | 7         | 5.72E-02 | 0.58  |
| 5          | +         | Other eye disorders | 75         | 41            | 14        | 4.76E-02 | 0.58  |
| 5          | +         | Neoplasms of unspecified nature or uncertain behavior | 60         | 39            | 6         | 8.58E-02 | 0.57  |
| 5          | +         | Blindness and vision defects | 58         | 33            | 11        | 9.89E-02 | 0.57  |
| 5          | +         | Nutritional deficiencies | 219        | 141           | 47        | 6.85E-02 | 0.54  |
| 5          | —         | HIV infection | 2          | 25            | 9         | 1.44E-02 | 0.69  |
| 5          | —         | Coronary atherosclerosis and other heart disease | 44         | 91            | 17        | 9.18E-03 | 0.6   |
| 5          | —         | Administrative/social admission | 61         | 97            | 9         | 2.20E-02 | 0.58  |
| 5          | —         | Disorders of lipid metabolism | 121        | 301           | 111       | 1.59E-03 | 0.56  |
| 5          | —         | Essential hypertension | 96         | 271           | 124       | 1.20E-02 | 0.55  |
| 5          | +         | Open wounds of extremities | 28         | 7             | 0         | 2.54E-04 | 0.8   |
| 5          | +         | Maintenance chemotherapy; radiotherapy | 14         | 5             | 1         | 5.77E-02 | 0.7   |
| 5          | +         | Cataract | 64         | 26            | 10        | 3.32E-03 | 0.64  |
| 6          | +         | Occlusion or stenosis of precerebral arteries | 22         | 10            | 3         | 8.77E-02 | 0.63  |
| 6          | +         | Acute bronchitis | 37         | 19            | 3         | 3.37E-02 | 0.63  |
| 6          | +         | Poisoning by other medications and drugs | 24         | 7             | 8         | 9.98E-02 | 0.62  |
| 6          | +         | Anal and rectal conditions | 29         | 14            | 5         | 9.67E-02 | 0.6   |
| 6          | +         | Other eye disorders | 87         | 43            | 14        | 7.69E-03 | 0.6   |
| 6          | +         | Nonmalignant breast conditions | 65         | 41            | 7         | 6.60E-02 | 0.58  |
| 6          | +         | Blindness and vision defects | 63         | 36            | 11        | 7.62E-02 | 0.57  |
| 6          | +         | Inflammation; infection of eye (except that caused by tuberculosis or sexually transmitted disease) | 78         | 39            | 20        | 6.19E-02 | 0.57  |
| 10         | +        | Nutritional deficiencies | 228        | 143           | 47        | 3.51E-02 | 0.55  |

Published studies32–36, and we confirmed that these medications modulated the risks of Lyme comorbidities, including fluticasone–‘cataract’ (adjusted OR = 1.94, p = 0.072 at 5 years; adjusted OR = 2.01, p = 0.033 at 10 years) hydrochlorothiazide–‘neoplasms of unspecified nature or uncertain behavior’ (adjusted OR = 2.23, p = 0.031 at 5 years; adjusted OR = 2.48, p = 0.0092 at 10 years), metformin–‘nutritional deficiencies’ (adjusted OR = 2.05, p = 0.097 at 10 years), and esomeprazole–‘nutritional deficiencies’ (adjusted OR = 1.75, p = 0.093 at 10 years).

Five antibiotics, doxycycline, azithromycin, levofloxacin, clavulanate, and mupirocin, and one antiviral drug, valacyclovir, were predicted to modulate the risk of subsequent comorbidities. Doxycycline, a first-line antibiotic that was the most prescribed antibiotic in our EMR for patients with LD (39%, N = 553), was associated with an elevated risk of eye disorders, including ‘cataract’ (adjusted OR = 2.05, p = 0.092 at 2 years; adjusted OR = 1.70, p = 0.067 at 10 years), ‘blindness and vision disorders’ (adjusted OR = 2.05, p = 0.016 at the 5 years; adjusted OR = 1.95, p = 0.019 at 10 years), and ‘other eye disorders’ (adjusted OR = 1.81, p = 0.024) (Fig. 2A).

In regard to ‘nutritional deficiencies’, 11 medications were predicted to be risk factors and three to be protective. Among the 11 risk factor medications were two antibiotics, levofloxacin (adjusted OR = 2.26, p = 0.0093 at 5 years; adjust OR = 2.77, p = 7.0E-4 at 10 years) and clavulanate (adjusted OR = 1.64, p = 0.094 at 10 years), and one antiviral prophylactic, valacyclovir (adjusted OR = 2.56, p = 0.014 at 5 years; adjusted OR = 2.58, p = 0.011 at 10 years). Interestingly, we could identify potential new therapeutic options for the LD adjunctive treatment that warrant further study and replication analyses. Three medications, propofol, docusate, and heparin, consistently were associated with
### Table 2. Diseases associated with Lyme, by ICD-9 code. A total of 3,639 diseases were tested. This table includes only the ICD-9 diseases that are classified into the CCS-single-level categories shown in (a), and a full list of associations is provided in Supplementary Table 1.

| Time (year) | Direction | Disease (CCS) | ICD9 | Disease (ICD9) | Lyme First | Disease First | Same Time | p value (binomial) | Prob. (binomial) | p value (logistic regression) | OR (logistic regression) |
|------------|-----------|---------------|------|---------------|------------|---------------|-----------|-------------------|----------------|------------------------|----------------------|
| 5          | —         | HIV infection | V08  | HIV positive NOS | 0          | 21            | 8         | 1.21E-02          | 0.72           | 1.80E-05               | 2.17                 |
| 5          | —         | Administrative/social admission | V20.2  | Routin child health exam | 16          | 49            | 4         | 3.18E-04          | 0.71           | 1.31E-02               | 2.08                 |
| 5          | +         | Nutritional deficiencies | 268.9  | Vitamin D deficiency NOS | 203        | 124           | 36        | 1.37E-02          | 0.56           | 1.20E-17               | 5.64                 |
| 5          | +         | Cataract | 366.9  | Cataract NOS | 40          | 18            | 7         | 4.08E-02          | 0.62           | 2.90E-30               | 4.27                 |
| 5          | +         | Acute bronchitis | 466.0  | Acute bronchitis | 36          | 16            | 3         | 1.50E-02          | 0.65           | 4.02E-21               | 3.56                 |
| 5          | +         | Nonmalignant breast conditions | 793.80  | Unspecified abnormal mammagram | 28          | 12            | 0         | 8.29E-03          | 0.70           | 8.92E-10               | 2.61                 |
| 10         | —         | HIV infection | V08  | HIV positive NOS | 0          | 24            | 8         | 3.50E-03          | 0.75           | 1.80E-05               | 2.17                 |
| 10         | —         | Disorders of lipid metabolism | 272.0  | Hyperlipidemia NEC/NOS | 84          | 159           | 50        | 8.04E-02          | 0.54           | 1.60E-30               | 2.22                 |
| 10         | —         | Disorders of lipid metabolism | 272.4  | Hyperlipidemia NEC/NOS | 97          | 187           | 64        | 9.01E-02          | 0.54           | 1.06E-18               | 1.78                 |
| 10         | —         | Essential hypertension | 401.9  | Hypertension NOS | 96          | 247           | 120       | 8.16E-02          | 0.53           | 9.83E-08               | 1.39                 |
| 10         | —         | Administrative/social admission | V20.2  | Routin child health exam | 17          | 54            | 4         | 8.82E-05          | 0.72           | 1.31E-02               | 2.08                 |
| 10         | +         | Nutritional deficiencies | 268.9  | Vitamin D deficiency NOS | 211        | 124           | 36        | 4.67E-03          | 0.57           | 1.20E-17               | 5.64                 |
| 10         | +         | Cataract | 366.16  | Senile nuclear cataract | 17          | 2             | 1         | 1.29E-03          | 0.85           | 2.94E-03               | 1.97                 |
| 10         | +         | Cataract | 366.9  | Cataract NOS | 45          | 21            | 7         | 3.02E-02          | 0.62           | 2.90E-30               | 4.27                 |
| 10         | +         | Inflammation; infection of eye (except that caused by tuberculosis or sexually transmitted disease) | 373.00  | Blepharitis NOS | 33          | 2             | 1         | 1.14E-07          | 0.92           | 2.27E-14               | 3.79                 |
| 10         | +         | Other eye disorders | 375.15  | Tear film insuffic NOS | 24          | 11            | 1         | 3.26E-02          | 0.67           | 4.43E-12               | 3.36                 |
| 10         | +         | Acute bronchitis | 466.0  | Acute bronchitis | 37          | 17            | 3         | 1.66E-02          | 0.65           | 4.02E-21               | 3.56                 |
| 10         | +         | Nonmalignant breast conditions | 793.80  | Unspecified abnormal mammogram | 31          | 12            | 0         | 2.70E-03          | 0.72           | 8.92E-10               | 2.61                 |

... (continued)
We identified 16 medications associated with disease comorbidities within 5 years post-LD, 81% (13/16) of which overlapped with those identified as associated 10 years post-Lyme by the CCS-single-level categorization. Specifically, five out of six anti-infective drugs, doxycycline, azithromycin, levofloxacin, mupirocin, and valacyclovir, appeared in both timeframes. Moreover, 22 medications were associated with the ICD-9–level disease comorbidities within 5 years after Lyme, 95% (21/22) of which were also identified in the 10-year post-Lyme analysis. Among those 21 medications, five are antibiotics (doxycycline, amoxicillin, azithromycin, ciprofloxacin, mupirocin) and one is an antiviral drug (valacyclovir). The four medications associated with comorbidities exclusively in the 5 years post-Lyme, clavulanate, gabapentin, midazolam, and fentanyl, may impact relatively early Lyme comorbidities (Supplementary Fig. 1).

Figure 2. Medication–Lyme disease comorbidity network, analyzed by CCS-single-level categories, in time windows of 5 years (A) and 10 years (B). Significant associations between medications (cyan) and comorbidities (magenta) are connected by red or blue lines (p < 0.1). Red lines indicate risk associations (OR > 1), and blue lines indicate protective associations (OR < 1). Medications and indications (green) were connected based on information in the public knowledgebase MEDI\textsuperscript{44}.

p = 9.1E-4 at 10 years) and a steroid, methylprednisolone (adjusted OR = 2.14, p = 0.027 at 5 years/adjusted OR = 2.31, p = 0.0077 at 10 years).

**Medications that modulate LD pathophysiology on different timescales.** We identified 16 medications associated with disease comorbidities within 5 years post-LD, 81% (13/16) of which overlapped with those identified as associated 10 years post-Lyme by the CCS-single-level categorization. Specifically, five out of six anti-infective drugs, doxycycline, azithromycin, levofloxacin, mupirocin, and valacyclovir, appeared in both timeframes. Moreover, 22 medications were associated with the ICD-9–level disease comorbidities within 5 years after Lyme, 95% (21/22) of which were also identified in the 10-year post-Lyme analysis. Among those 21 medications, five are antibiotics (doxycycline, amoxicillin, azithromycin, ciprofloxacin, mupirocin) and one is an antiviral drug (valacyclovir). The four medications associated with comorbidities exclusively in the 5 years post-Lyme, clavulanate, gabapentin, midazolam, and fentanyl, may impact relatively early Lyme comorbidities (Supplementary Fig. 1).
A total of 17 medications overlapped between the CCS-single and ICD-9 levels in either the 5-year or 10-year time windows. Five of them were anti-infective drugs, namely doxycycline, azithromycin, levofloxacin, mupirocin, and valacyclovir. In the 5-year time window, 16 medications were associated with comorbidities classified by CCS-single-level category, of which 50% (8/16) were also identified at the ICD-9 level. At 10 years post-Lyme diagnosis, we identified 21 significant associations between medications and comorbidities, of which 81% (17/21) were consistent with those identified at the ICD-9 level.

Figure 3. Medication–Lyme disease comorbidity network at the ICD-9 levels in time windows of 5 years (A) and 10 years (B). Significant associations between medications (cyan) and comorbidities (magenta) are connected by red or blue lines (p < 0.1). Red lines indicate risk associations (OR > 1), and blue lines indicate protective associations (OR < 1).
By the cross-sectional analysis described above, we demonstrated that certain medications increased risk or protected against disease comorbidities in patients with LD. At higher resolution (i.e., ICD-9 codes) with 10-year follow up, we found that doxycycline, the most commonly used antibiotic for treatment of LD\textsuperscript{9}, protected against ‘backache NOS’ and ‘chronic rhinitis’, but increased risk of ‘ear film insuffic NOS’ and ‘cataract NOS’. Another commonly used antibiotic, amoxicillin, was associated with elevated risk of ‘acute URI NOS’.

To clarify the longitudinal effects of doxycycline and amoxicillin, we analyzed these associations by propensity-score-matched survival analyses (Table 3). The doxycycline-treated group was significantly older than the untreated group (P = 0.007), whereas the amoxicillin-treated group was significantly younger than the untreated group (P = 8.7E-4). In addition, doxycycline was prescribed more frequently to male than female patients (P = 0.03). The doxycycline/amoxicillin-treated groups had higher prevalence of certain pre-existing comorbidities and a higher prescription rate of particular medications than the untreated groups (Supplementary Table 4). Moreover, both the doxycycline/amoxicillin treated groups had higher propensity scores than the corresponding untreated groups (P < 0.001).

After propensity score matching, the control cohorts were well balanced with the treated groups in terms of observed covariates (Supplementary Table 4). This analysis revealed that the risk of ‘backache NOS’ (Fig. 4a) and ‘chronic rhinitis’ (Fig. 4b) was significantly lower in the doxycycline-treated cohort than in the untreated cohort (HR = 0.42, p = 0.020; HR = 0.49, p = 0.040, respectively; Table 3). Furthermore, Kaplan-Meier curves demonstrated that the cumulative probabilities of remaining free from ‘cataracts NOS’ and ‘ear film insuffic NOS’ were lower among doxycycline-treated patients, but did not reach statistical significance (p = 0.0672 and 0.0608, respectively; Supplementary Fig. 2a,b). Cox regression analysis suggested a trending association between doxycycline usage and increased risk of both ‘cataract NOS’ and ‘ear film insuffic NOS’ (HR = 1.90, p = 0.071). On the other hand, patients prescribed amoxicillin had significantly higher hazard ratios for ‘acute URI NOS’ (HR = 2.26, p = 0.0091; Fig. 4c). Therefore, the effects of doxycycline and amoxicillin revealed by the cross-sectional analysis were confirmed by survival analyses using the propensity score-matched cohort for many of the associations (Table 3).

**Survival analysis of first-line medications in propensity-matched populations.** By the cross-sectional analysis described above, we demonstrated that certain medications increased risk or protected against disease comorbidities in patients with LD. At higher resolution (i.e., ICD-9 codes) with 10-year follow up, we found that doxycycline, the most commonly used antibiotic for treatment of LD\textsuperscript{9}, protected against ‘backache NOS’ and ‘chronic rhinitis’, but increased risk of ‘ear film insuffic NOS’ and ‘cataract NOS’. Another commonly used antibiotic, amoxicillin, was associated with elevated risk of ‘acute URI NOS’.

To clarify the longitudinal effects of doxycycline and amoxicillin, we analyzed these associations by propensity-score-matched survival analyses (Table 3). The doxycycline-treated group was significantly older than the untreated group (P < 0.007), whereas the amoxicillin-treated group was significantly younger than the untreated group (P = 8.7E-4). In addition, doxycycline was prescribed more frequently to male than female patients (P < 0.03). The doxycycline/amoxicillin-treated groups had higher prevalence of certain pre-existing comorbidities and a higher prescription rate of particular medications than the untreated groups (Supplementary Table 4). Moreover, both the doxycycline/amoxicillin treated groups had higher propensity scores than the corresponding untreated groups (P < 0.001).

After propensity score matching, the control cohorts were well balanced with the treated groups in terms of observed covariates (Supplementary Table 4). This analysis revealed that the risk of ‘backache NOS’ (Fig. 4a) and ‘chronic rhinitis’ (Fig. 4b) was significantly lower in the doxycycline-treated cohort than in the untreated cohort (HR = 0.42, p = 0.020; HR = 0.49, p = 0.040, respectively; Table 3). Furthermore, Kaplan-Meier curves demonstrated that the cumulative probabilities of remaining free from ‘cataracts NOS’ and ‘ear film insuffic NOS’ were lower among doxycycline-treated patients, but did not reach statistical significance (p = 0.0672 and 0.0608, respectively; Supplementary Fig. 2a,b). Cox regression analysis suggested a trending association between doxycycline usage and increased risk of both ‘cataract NOS’ and ‘ear film insuffic NOS’ (HR = 1.90, p = 0.072; HR = 2.65, p = 0.071). On the other hand, patients prescribed amoxicillin had significantly higher hazard ratios for ‘acute URI NOS’ (HR = 2.26, p = 0.0091; Fig. 4c). Therefore, the effects of doxycycline and amoxicillin revealed by the cross-sectional analysis were confirmed by survival analyses using the propensity score-matched cohort for many of the associations (Table 3).

**Discussion**

Proper diagnosis, treatment, and management of Lyme Disease (LD) are difficult for a variety of reasons. In particular, the complex interplay between various treatments and current clinical status, including disease burden, can lead to a wide range of sequelae. This study represents the first data-driven effort to identify clinical factors that affect treatment of LD patients, verified by manual chart review, using large-scale EMR data. In contrast to a one-size-fits-all strategies, our approach may facilitate the personalization of treatment regimens based on the clinical profiles (i.e., disease burden) of affected individuals. This strategic transition is essential in light of the variability in efficacy of antibiotics and the adverse events associated with these treatments (see Supplementary Discussion for further details).

In addition to the co-morbid conditions that present before LD infection (see Supplementary Discussion), we identified conditions that are more likely to be present after a LD diagnosis than beforehand, consistent with the possibility that these diseases are side effects or complications arising from Lyme infection. Many of these associations (e.g., eye-related disorders) are well documented, enhancing our confidence in our results.

The results of this analysis feed into our drug-comorbidity associations network and can be used to inform treatment regimens. For instance, we found that use of steroid medications is associated with increased risk for the symptoms common to Post-Treatment Lyme Disease Syndrome (see Supplementary Discussion). Other findings from our drug-comorbidity network might facilitate personalization of treatment regimens, with more favorable clinical outcomes for patients. For example, several anti-infectious drugs, pain relievers such as diclofenac and hydrocodone, and the anti-allergy medication azelastine were also associated with higher rates of nutritional deficiencies, suggesting that physicians should consider recommending vitamin supplements for patients receiving these treatments.

Doxycycline is already associated with a range of side effects, including pain, increased pressure inside the skull\textsuperscript{15}, and gastrointestinal injury\textsuperscript{16}. The nuances of these associations are not well understood. We also found that doxycycline use was associated with lower risk of ‘backache NOS’, often reported a symptom of PTLS, and lower rates of ‘chronic rhinitis’. This medication showed a trend for risks to cataract (HR = 1.90, p = 0.072), tear film insufficiency (HR = 2.65, p = 0.071) in the survival analyses, which require further validation in both short-term and long-term prospective trials.

This study had several limitations. We did not use a non-LD control cohort for our analyses. A large issue is the relative low LD sample size, which is a consequence of our hospital’s location in the metropolitan area of NYC (https://www.health.ny.gov/statistics/chac/general/g40.htm). Based on the de-identified EMR system we utilized,
LD two-tier antibody test results were documented as free text which was masked as PHI content and we do not have capacity to review all charts from EPIC system. As such, due to data availability and sparseness of other clinical variables (e.g., lab test results), we relied on ICD-9 code-based identification of LD patients. However, with a randomly selected patient cohort (N = 50) and physician’s manually chart review, we achieved PPV = 96% with considering three equivocal results, suggesting a strong confidence of identifying true positive LD patients. With our manual chart review approach, however, we were unable to evaluate a false negative rate. As tick bites are most likely to occur in surrounding rural locations in which forests are present, many patients may be initially diagnosed in a different facility, and then come to MSH for follow-up treatment. Another limitation is related to the close proximity of MSH to other medical centers in the area. Specifically, patients may seek treatment at other nearby hospitals, resulting in the loss of valuable information from our EMR system. Finally, because we do not have access to patients’ historic EMR data from outside of MSH, our temporal analyses may not accurately capture the true timeline of acquisition of disease comorbidities. We reported nominal p-values without multiple test correction, because this study is a small-scale, exploratory study. This study will facilitate future work involving cohorts from multiple institutions which will generate more robust findings. We are currently performing an external replication analysis at another academic medical center, and the results of this effort may bolster our conclusions. Furthermore, utilization of a larger LD sample size across multiple medical centers would enable us to analyze combinatorial effects of multiple medications to possible comorbidities, which are also important for management of LD patients. Additionally, we are applying the findings from our current study in order to model explicit, optimal treatment recommendations at the patient level.

Our study is the first to investigate a comprehensive and racially diverse EMR with the aim of discovering the detailed clinical profiles of patients before and after diagnosis of LD. We applied machine learning models and identified a list of medications, including antibiotics that are recommended for treatment, which represent possible risk factors for PTLDs. While we are unable to infer causation from our analyses, further study of the associations we identified could hopefully one day be utilized by physicians to tailor treatments for LD patients based on their current and past physiological state. In addition, we hope to investigate the contributions of genomics and genetic variants to differences pathophysiology. From this work, we hope to enhance not only the success rates of LD treatment, but also to facilitate preemptive strategies for managing high-risk ensuing conditions. All of our findings and recommendations, of course, require further investigation and validation experiments.

Figure 4. Kaplan–Meier plot of propensity-score-matched survival analysis (a) doxycycline–‘backache NOS’ (ICD-9 code: 724.5), (b) doxycycline–‘chronic rhinitis’ (472.0), and (c) amoxicillin–‘acute URI NOS’ (465.9).
Methods

The study was specifically governed and approved by Institutional Review Board approval at MSH (GCO 15–1805). All patient records were de-identified and analyzed retrospectively, and as such, no informed consent was required. All methods were performed in accordance with the relevant guidelines and regulations.

Patient population and standardization of clinical terminology. Patient cohort. We provide a schematic of our study design, approach, and patient selection criteria in Fig. 1. We utilized Electronic Medical Records (EMRs) from the Mount Sinai Data Warehouse (MSDW), the largest comprehensive EMR system in New York City, which includes data from a racially and ethnically diverse patient base. In this study, we retrieved records from all patients diagnosed with Lyme disease (LD) with the ICD-9 code 088.81 (n = 2,134). We restricted the data to records occurring between 2000 and 2015, allowing for up to 15-year follow-up. Finally, we only kept data from patients with defined age, self-reported sex, and self-reported race/ethnicity (referred to as “race” in this manuscript) (n = 1,767). For this cohort, there were 930 females (52.6%) and 837 males (47.4%), with an average age of 47.8 ± 19.7. The racial breakdown of the cohort is as follows: 1,201 Caucasian (70.0%), 49 African-American (2.8%), 34 Hispanic/Latino (1.9%), and 483 Others (27.3%). For these patients, we also retrieved all other available clinical variables from EMR, including prescriptions and other disease diagnoses. In total, we compiled 3,936 disease diagnoses and 5,723 prescriptions.

Manual chart reviews. Since antibody tests were reported as free text and masked in our de-identified EMR data, a physician performed manual chart reviews for a random subset of the LD cohort (n = 50) within the same year of the LD diagnosis to evaluate the accuracy of the phenotyping. The available antibody test was “Lyme Total Antibody with Reflex Western Blot”, coded with CPT code of 86618. Among the 50 reviewed putative LD patients, 45 were reported as positive, two were reported as negative, and three were reported as equivocal results, indicating no clear interpretation of the either positive or negative. The chart review yields a positive predictive value of 0.96 with considering equivocal results. Given the fact that two-tiered antibody diagnostic testing would not detect all true positives and can produce up to 50% false negatives37, we were confident in our selection strategy for LD patients in our Mount Sinai EMR.

Statistical methods and analysis. Disease pair temporal directionality. For all patients with LD, we first assessed disease-pair connectivity patterns for comorbid diseases. Specifically, we determined whether the members of each pair exhibited a significant pattern in their temporal order, e.g., whether one preceded the other more often than expected by chance. We performed a cumulative binomial probability test to assess the temporal ordering of the associations between Lyme and all other diseases, assuming a 50% probability of either to occur before the other. We performed the following analysis on both broad and narrow disease categories (see Supplemental Methods).

At the broader level, we analyzed representative CCS-single-level categories because this strategy could enhance signals that might be lost due to small sample size at the ICD-9 level. Second, we performed the analysis using standard ICD-9 codes in order to detect associations at a higher resolution for certain codes that may be more prevalent. Because these comorbid conditions can be either chronic or acute, we performed several iterations of this analysis over different time windows, specifically 2, 5, and 10 years. For each time window, we restricted collection of information for the comorbid diseases in both temporal directions, relative to the date of first Lyme diagnosis. For the 2-year window, for example, we only collected disease data for each patient 2 years before and 2 years after the date of Lyme diagnosis. For the CCS-single- and ICD-9–level analyses, we performed 275 and 3,639 tests for each window, respectively. Last, to determine whether disease pairs with significant temporal directionality were also significantly comorbid, we performed a logistic regression for each pair controlling for age, sex, and self-reported race. The outcome variable in this model was the disease that was shown to occur after the other in the temporal analysis (significant in the binomial assessment).

Definition of outcomes and covariates in the statistical model. To discover risk factors or new therapeutic options for LD sequelae, we focused on the new onset of disease comorbidities more than 7 days after the diagnosis of LD. Of the 1,767 LD patients in the overall cohort, we systematically assessed the comorbidities and medication associations for 1,183 patients who were followed up for more than 7 days and had at least one prescription record in MSH’s EMR system. Like our disease-pair temporal directionality analysis, we set time windows of 2, 5, and 10 years. For each patient, we collected the diseases diagnosed within 2, 5, or 10 years after their first Lyme diagnosis date. We also retrieved medications prescribed within 1 year prior to and 2, 5, or 10 years after the first Lyme diagnosis. Outcome comorbidities were defined by ICD-9 code and categorized using CCS-single-level Diagnosis terms.

Feature selection. We considered many disease variables, coded by CCS-single-level categories, and medication variables, which were mapped to RxNorm ingredient codes. Accordingly, we adopted a feature selection method, penalized logistic regression with the adaptive LASSO (Eq. 1), to identify variables of the highest relevance that associated with ensuing comorbidities following LD diagnosis. The adaptive LASSO is an extension of the traditional LASSO38 that uses coefficient-specific weights39. The adaptive LASSO estimator may achieve sparsity and selection consistency for the true model, i.e., correctly identifies the zero and nonzero parameters40. Let \( L_n(\beta; Y, X) \) be the negative log-likelihood parametrized by \( \beta \) for a sample of size n. The adaptive LASSO estimator is defined as:
\[
\hat{\beta} = \arg\min_{\beta} \{ \mathcal{L}(\beta; Y, X) + \lambda \sum_{j=1}^{d} \| \beta_j \| \}
\]

(1)

where \( \beta_j = [\beta_j^1, \ldots, \beta_j^n] \) is a coefficient specific weights vector, and \( \lambda_j \) is a regularization parameter. We set the positive constant \( \gamma \) as 1 according to Zou \textit{et al.} \cite{39}, and obtained \( \hat{\beta} \) by the maximum likelihood estimate of Ridge regression. The \( \lambda_j \) value for minimum AUC was chosen by 10-fold cross validation. We used the R package glmnet\cite{41} for these penalized regressions.

**Logistic regression model.** We used odds ratio (OR) from logistic regression (Eq. 2) to assess the risk of future comorbidity progression on each medication taken (i.e. either increased risk or protective effect). We analyzed the pairs of outcome disease comorbidity and the medications that were selected by the adaptive LASSO. In this model, we adjusted for age, sex, self-reported race, and the follow-up time frame.

\[
\log \left( \frac{P}{1 - P} \right) = \beta_0 + \beta_m \text{medication} + \beta_{age} + \beta_{gender} + \beta_{race} + \beta_{observed \ period}
\]

(2)

where \( P \) is the probability of a disease, medication is a binary variable, age is a continuous parameter, gender is a binary variable (Female/Male), race is a categorical variable (Caucasian, African American, Hispanic/Latino, or Other), and observed period is a continuous parameter. \( \beta \) coefficients for each covariate represent the effect size when controlling for all others.

**Propensity score matching.** To control for potential confounding factors due to imbalances of clinical characteristics, not limited to age and gender, we analyzed the temporal effects of medications after the propensity score matching to select an appropriate control cohort for the targeted case cohort\cite{43}. Thus, we created comparable cohorts, consisting of groups treated or untreated with a targeted medication, based on a set of covariates at the baseline time point, i.e., time zero for each patient. The baseline time point was defined as the first prescription of the targeted medication or 7 days after LD diagnosis, whichever was later, because we observed disease comorbidities for more than 7 days after LD diagnosis.

The propensity scores of targeted prescriptions were predicted by a logistic regression model, including other significant medications and disease confounders selected by the adaptive LASSO with a 10-year time window, with patient demographics as covariates. Each patient prescribed a given medication was matched to a corresponding comparison patient (1:1 ratio) by nearest-neighbor matching. For instance, we analyzed association corresponding comparison patient (1:1 ratio) by nearest-neighbor matching. For instance, we analyzed association between doxycycline and ‘backache Not Otherwise Specified (NOS)’ (ICD-9 code: 724.5), ‘chronic rhinitis’ (472.0), ‘tear film insufficiency (insuffic) NOS (375.15),’ and ‘cataract NOS (366.9),’ and between amoxicillin and ‘acute upper respiratory infection (URI) NOS (465.9).’ A total of 328, 330, 358, 370, and 115 subjects were selected corresponding comparison patient (1:1 ratio) by nearest-neighbor matching. For instance, we analyzed association between doxycycline and ‘backache Not Otherwise Specified (NOS)’ (ICD-9 code: 724.5), ‘chronic rhinitis’ (472.0), ‘tear film insufficiency (insuffic) NOS (375.15),’ and ‘cataract NOS (366.9),’ and between amoxicillin and ‘acute upper respiratory infection (URI) NOS (465.9).’ A total of 328, 330, 358, 370, and 115 subjects were selected for each medication-comorbidity pair in the propensity score-matched treated/untreated group. The R package MatchIt\cite{43} was used for propensity score matching.

**Survival analysis.** We generated survival curves by the Kaplan–Meier method and examined differences in survival among subgroups by the log-rank test, with propensity score matching of cases and controls. We calculated hazard ratios using Cox proportional hazards models:

\[
h(t) = h_0(t) \exp(\beta_m \text{medication})
\]

(3)

where \( h(t) \) is the expected hazard at time \( t \), \( h_0(t) \) is the baseline hazard, and medication is a binary variable. We verified the proportional hazards assumption by confirming that Schoenfeld residuals are independent of time (Schoenfeld test p > 0.1). We used the R packages survival and survminer for the survival analysis.

**References**

1. Kuehn, B. M. CDC estimates 300,000 US cases of Lyme disease annually. \textit{JAMA} \textbf{310}, 1110, https://doi.org/10.1001/jama.2013.278331 (2013).
2. Nelson, C. A. \textit{et al.} Incidence of Clinician-Diagnosed Lyme Disease, United States, 2005–2010. \textit{Emerg Infect Dis} \textbf{21}, 1625–1631, https://doi.org/10.3201/eid2109.150417 (2015).
3. Steere, A. C. Lyme disease. \textit{N Engl J Med} \textbf{345}, 115–125, https://doi.org/10.1056/NEJMo0107123450207 (2001).
4. Shapiro, E. D. Clinical practice. \textit{Lyme disease. N Engl J Med} \textbf{370}, 1724–1731, https://doi.org/10.1056/NEjmc1314325 (2014).
5. Wormser, G. P. \textit{et al.} Borrelia burgdorferi genotype predicts the capacity for hematogenous dissemination during early Lyme disease. \textit{J Infect Dis} \textbf{198}, 1358–1364, https://doi.org/10.1093/infdis/jir130 (2008).
6. Hanincova, K. \textit{et al.} Multilocus sequence typing of Borrelia burgdorferi suggests existence of lineages with differential pathogenic properties in humans. \textit{Plos One} \textbf{8}, e37066, https://doi.org/10.1371/journal.pone.0037066 (2013).
7. Koedel, U., Fingerle, V. \& Pfister, H. W. Lyme neuroborreliosis-epidemiology, diagnosis and management. \textit{Nat Rev Neuro} \textbf{11}, 446–456, https://doi.org/10.1038/nrneurol.2015.121 (2015).
8. Baldwin, K. D., Brusals, C. M., Nduagubata, A. M. \& Sankar, W. N. Predictive Factors for Differentiating Between Septic Arthritis and Lyme Disease of the Knee in Children. \textit{J Bone Joint Surg Am} \textbf{98}, 721–728, https://doi.org/10.2106/JBJS.14.01331 (2016).
9. Wormser, G. P. \textit{et al.} The clinical assessment, treatment, and prevention of lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. \textit{Clin Infect Dis} \textbf{43}, 1089–1134, https://doi.org/10.1086/508667 (2006).
10. Fedor, H. M. \textit{et al.} A critical appraisal of “chronic Lyme disease”. \textit{N Engl J Med} \textbf{357}, 1422–1430, https://doi.org/10.1056/NEJMra072023 (2007).
11. Halperin, J. J. Prolonged Lyme disease treatment: enough is enough. \textit{Neurology} \textbf{70}, 986–987, https://doi.org/10.1212/01.wnl.0000291407.40667.69 (2008).
12. Patel, R., Grogg, K. L., Edwards, W. D., Wright, A. J. \& Schwenk, N. M. Death from inappropriate therapy for Lyme disease. \textit{Clin Infect Dis} \textbf{31}, 1107–1109, https://doi.org/10.1086/318138 (2000).
13. Klemmper, M. S. et al. Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme disease. N Engl J Med 345, 85–92, https://doi.org/10.1056/NEJM200107122450202 (2001).

14. Fallon, B. A. et al. A randomized, placebo-controlled trial of repeated IV antibiotic therapy for Lyme encephalopathy. Neurology 70, 992–1003, https://doi.org/10.1212/01.WNL.0000284604.61160.2D (2008).

15. Finch, C. et al. Integrated assessment of behavioral and environmental risk factors for Lyme disease infection on Block Island, Rhode Island. PLoS One 9, e84758, https://doi.org/10.1371/journal.pone.0084758 (2014).

16. Guerra, M. et al. Predicting the risk of Lyme disease: habitat suitability for Ixodes scapularis in the north central United States. Emerg Infect Dis 8, 289–297, https://doi.org/10.3201/eid0803.010166 (2002).

17. Cantorna, M. T. & Hayes, C. E. Vitamin A deficiency exacerbates murine Lyme arthritis. J Infect Dis 174, 747–751 (1996).

18. Cristea, V. & Crisan, M. Lyme disease with magnesium deficiency. Magnes Res 16, 287–289 (2003).

19. Ormerod, L. D., Puklin, J. E. & Giles, C. L. Chronic Propionibacterium acnei endophthalmitis as a cause of intermediate uveitis. Ocul Immunol Inflamm 5, 67–68 (1997).

20. Heinz, C., Schoonbrood, S. & Heijenroda, A. Intermediate uveitis in children and young adults: differences in clinical course, associations and visual outcome. Br J Ophthalmol 98, 1107–1111, https://doi.org/10.1136/bjo.2013-304589 (2014).

21. Toledo, A., Monzon, J. D., Coleman, J. L., Garcia-Monco, J. C. & Benach, J. L. Hypercholesterolemia and ApoE deficiency result in severe infection with Lyme disease and relapsing fever Borrelia. Proc Natl Acad Sci USA 112, 5491–5496, https://doi.org/10.1073/pnas.1502581112 (2015).

22. Wang, J. J. et al. Use of inhaled and oral corticosteroids and the long-term risk of cataract. Ophthalmology 116, 652–657, https://doi.org/10.1016/j.ophtha.2008.12.001 (2009).

23. Pottegard, A. et al. Hydrochlorothiazide use is strongly associated with risk of lip cancer. J Intern Med 282, 322–331, https://doi.org/10.1111/j.1365-2604.2012.05629.x (2012).

24. Friedman, G. D., Udaltsova, N., Chan, J., Quesenberry, C. P. Jr. & Habel, L. A. Screening pharmaceuticals for possible carcinogenic effects: initial positive results for drugs not previously screened. Cancer Causes Control 20, 1821–1835, https://doi.org/10.1007/s10552-009-9375-2 (2009).

25. Nafar, M., Haei, F., Porhamoyan, J. & Naderi, N. D. The role of metformin on vitamin B12 deficiency: a meta-analysis review. Intern Emerg Med 10, 93–102, https://doi.org/10.1007/s11739-014-1157-5 (2015).

26. Heidelbaugh, J. J. Proton pump inhibitors and risk of vitamin and mineral deficiency: evidence and clinical implications. Ther Adv Drug Saf 4, 125–133, https://doi.org/10.1177/2042098613482843 (2013).

27. Straubinger, R. K., Straubinger, A. F., Summers, B. A. & Jacobson, R. H. Status of Borrelia burgdorferi infection after antibiotic treatment and the effects of corticosteroids: An experimental study. J Infect Dis 181, 1069–1081, https://doi.org/10.1093/infdis/jit340 (2000).

28. Jowett, N., Gaudin, R. A., Banks, C. A. & Hadlock, T. A. Steroid use in Lyme disease-associated facial palsy is associated with worse long-term outcomes. Laryngoscope 127, 1451–1458, https://doi.org/10.1002/lary.26273 (2017).

29. Stahlmann, R. & Lode, H. Safety considerations of fluoroquinolones in the elderly: an update. Drugs Aging 27, 193–209, https://doi.org/10.1007/s11202-009-9000-9 (2010).

30. Gultuna, S. et al. Ciprofloxacin induced tendinitis. J Clin Rheumatol 15, 201–202, https://doi.org/10.1097/RHU.0b013e3181a7b0d4 (2009).

31. Kuhn, M., Campillos, M., Letunic, I., Jensen, L. J. & Bork, P. A side effect resource to capture phenotypic effects of drugs. Mol Syst Biol 5, 343, https://doi.org/10.1038/msb.2009.98 (2010).

32. Kuhn, M., Letunic, I., Jensen, L. J. & Bork, P. The SIDER database of drugs and side effects. Nucleic Acids Res 44, D1075–1079, https://doi.org/10.1093/nar/gkv1075 (2016).

33. Donato, S. T. Issues in the diagnosis and treatment of Lyme disease. Open Neurol J 6, 140–145, https://doi.org/10.2174/1874201406661704.2012.

34. Abbott, R. A., Hammans, S., Margarson, M. & Aji, B. M. Diaphragmatic paralysis and respiratory failure as a complication of Lyme disease. J Neurol Neurosurg Psychiatry 76, 1306–1307, https://doi.org/10.1136/jnp.2004.046284 (2005).

35. Lochhead, J. & Elston, J. S. Doxycycline induced intracranial hypertension. BMJ 326, 641–642, https://doi.org/10.1136/bmj.326.7406.641 (2003).

36. Affolter, K., Samowitz, W., Boynton, K. & Kelly, E. D. Doxycycline-induced gastrointestinal injury. Hum Pathol 66, 212–215, https://doi.org/10.1016/j.humpath.2017.02.011 (2017).

37. Branda, J. A., Linskey, K., Kim, Y. A., Steere, A. C. & Ferraro, M. J. Two-tiered antibody testing for Lyme disease with use of 2 enzyme immunoassays, a whole-cell sonicate enzyme immunoassay followed by a VlsE C6 peptide enzyme immunoassay. Clin Infect Dis 53, 141–147, https://doi.org/10.1093/cid/cia646 (2011).

38. Tibshirani, R. Regression shrinkage and selection via the lasso. Journal of the Royal Statistical Society. Series B (Methodological), 267–288 (1996).

39. Zou, H. & Zhang, H. H. On the Adaptive Elastic-Net with a Diverging Number of Parameters. Ann Stat 37, 1733–1751, https://doi.org/10.1214/08-AOS5625 (2009).

40. Fan, J. & Li, R. Variable selection via nonconcave penalized likelihood and its oracle properties. Journal of the American statistical Association 96, 1348–1360 (2001).

41. Friedman, J., Hastie, T. & Tibshirani, R. Regularization Paths for Generalized Linear Models via Coordinate Descent. J Stat Softw 33, 1–22 (2010).

42. Little, R. J. & Rubin, D. B. Causal effects in clinical and epidemiological studies via potential outcomes: concepts and analytical approaches. Ann Rev Public Health 21, 121–145, https://doi.org/10.1146/annurev.publhealth.21.1.121 (2000).

43. Ho, D. E., Imai, K., King, G. & Stuart, E. A. Matched nonparametric preprocessing for parametric causal inference. Journal of Statistical Software 42, 1–28 (2011).

44. Wei, W. Q., Mosley, J. D., Bastarche, L. & Denny, J. C. Validation and enhancement of a computable medication indication resource (ME DI) using a large practice-based dataset. AMIA Annu Symp Proc 2013, 1448–1456 (2013).

Acknowledgements

This study was funded by the Steven & Alexandra Cohen Foundation. We are grateful for Dr. Brian Fallon from Columbia University Medical Center for providing clinical insights and scientific support. We thank Savi Glowe, Eddyson Golden, and Francisco Santiago for administrative support. We thank Dr. Christopher Patil for providing edits. We thank Mount Sinai Data Warehouse for supporting data access.

Author Contributions

L.L. and J.D. were responsible for initial study design. L.L. was responsible for data collection. O.I. and B.L. were responsible for study implementation, interpreting the data, and ongoing management. O.I. and B.G. were responsible for statistical analysis, predictive models, literature review, and generating tables and figures. O.I., B.G., L.L., B.A.K. and J.D. and wrote and edited manuscript. N.G. performed manual chart review for the L.D. cohort. L.L. and J.D. supervised the study.
Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-019-41128-x.

Competing Interests: Dr. Dudley has received consulting fees or honoraria from Janssen Pharmaceuticals, GlaxoSmithKline, AstraZeneca, and Hoffman-La Roche; is a scientific advisor to LAM Therapeutics; and holds equity in NuMedii Inc., Ayasdi Inc., and Ontomics, Inc. Dr. Ichikawa is an employee of Sumitomo Dainippon Pharma Co., Ltd. The rest of authors declare no competing interests.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2019